JP5830015B2 - 合成グルコピラノシル脂質アジュバント - Google Patents

合成グルコピラノシル脂質アジュバント Download PDF

Info

Publication number
JP5830015B2
JP5830015B2 JP2012514187A JP2012514187A JP5830015B2 JP 5830015 B2 JP5830015 B2 JP 5830015B2 JP 2012514187 A JP2012514187 A JP 2012514187A JP 2012514187 A JP2012514187 A JP 2012514187A JP 5830015 B2 JP5830015 B2 JP 5830015B2
Authority
JP
Japan
Prior art keywords
mmol
antigen
gla
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012514187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528892A (ja
JP2012528892A5 (OSRAM
Inventor
スティーブン・ジー・リード
ダリック・カーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Access to Advanced Health Institute
Original Assignee
Infectious Disease Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Research Institute Inc filed Critical Infectious Disease Research Institute Inc
Publication of JP2012528892A publication Critical patent/JP2012528892A/ja
Publication of JP2012528892A5 publication Critical patent/JP2012528892A5/ja
Application granted granted Critical
Publication of JP5830015B2 publication Critical patent/JP5830015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP2012514187A 2009-06-05 2010-06-04 合成グルコピラノシル脂質アジュバント Active JP5830015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18470309P 2009-06-05 2009-06-05
US61/184,703 2009-06-05
PCT/US2010/037466 WO2010141861A1 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipid adjuvants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015162164A Division JP2016028042A (ja) 2009-06-05 2015-08-19 合成グルコピラノシル脂質アジュバント

Publications (3)

Publication Number Publication Date
JP2012528892A JP2012528892A (ja) 2012-11-15
JP2012528892A5 JP2012528892A5 (OSRAM) 2013-07-18
JP5830015B2 true JP5830015B2 (ja) 2015-12-09

Family

ID=43298190

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012514187A Active JP5830015B2 (ja) 2009-06-05 2010-06-04 合成グルコピラノシル脂質アジュバント
JP2015162164A Pending JP2016028042A (ja) 2009-06-05 2015-08-19 合成グルコピラノシル脂質アジュバント
JP2017040574A Active JP6251431B2 (ja) 2009-06-05 2017-03-03 合成グルコピラノシル脂質アジュバント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015162164A Pending JP2016028042A (ja) 2009-06-05 2015-08-19 合成グルコピラノシル脂質アジュバント
JP2017040574A Active JP6251431B2 (ja) 2009-06-05 2017-03-03 合成グルコピラノシル脂質アジュバント

Country Status (22)

Country Link
US (4) US8722064B2 (OSRAM)
EP (2) EP3124491B1 (OSRAM)
JP (3) JP5830015B2 (OSRAM)
CN (2) CN102481312B (OSRAM)
AU (1) AU2010256461B2 (OSRAM)
BR (1) BRPI1011072B1 (OSRAM)
CA (1) CA2764374C (OSRAM)
CY (1) CY1118347T1 (OSRAM)
DK (1) DK2437753T3 (OSRAM)
ES (1) ES2606563T3 (OSRAM)
HR (1) HRP20161585T1 (OSRAM)
HU (1) HUE031051T2 (OSRAM)
IL (2) IL216669A (OSRAM)
LT (1) LT2437753T (OSRAM)
MX (3) MX360448B (OSRAM)
PL (1) PL2437753T3 (OSRAM)
PT (1) PT2437753T (OSRAM)
RU (3) RU2732574C2 (OSRAM)
SI (1) SI2437753T1 (OSRAM)
SM (1) SMT201600437B (OSRAM)
TW (2) TWI549688B (OSRAM)
WO (1) WO2010141861A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016028042A (ja) * 2009-06-05 2016-02-25 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
NZ602217A (en) 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CA2826920A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EP3632463A1 (en) * 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2785370B1 (en) 2011-12-02 2021-07-21 Rhode Island Hospital Vaccine for falciparum malaria
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
BR112015000723A2 (pt) * 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
BR112015013440B1 (pt) 2012-12-13 2020-12-08 Aduro Biotech, Inc composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CA2908154C (en) 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
EA032441B1 (ru) * 2013-09-05 2019-05-31 Иммьюн Дизайн Корп. Вакцинные композиции против никотиновой зависимости
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) * 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CA2923026A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
CA2923028A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Mucosal vaccine composition
JP2015091794A (ja) 2013-10-03 2015-05-14 日東電工株式会社 注射ワクチン組成物
HK1219054A1 (zh) 2013-10-03 2017-03-24 日东电工株式会社 粘膜疫苗组合物
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
MA39228A1 (fr) 2014-01-21 2017-06-30 Immune Design Corp Compositions à utiliser pour le traitement d'états allergiques
MX375123B (es) 2014-02-14 2025-03-06 Immune Design Corp Composición para usarse en mejorar la respuesta inmune contra el cáncer.
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
WO2017090766A1 (ja) 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US11633411B2 (en) 2016-10-04 2023-04-25 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
CN110035772B (zh) * 2016-11-25 2023-07-18 财团法人牧岩生命科学研究所 水痘带状疱疹病毒疫苗
PE20191547A1 (es) 2016-12-26 2019-10-24 Mogam Inst Biomedical Res Composicion de vacuna contra el herpes zoster
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
AU2018330165B2 (en) * 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
BR112020004747A2 (pt) 2017-09-13 2020-09-24 Sanofi Pasteur composição imunogênica de citomegalovírus humano
EP3752182B1 (en) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like receptor ligands
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
TWI751513B (zh) 2019-03-18 2022-01-01 美商詹森藥物公司 E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
ES2987890T3 (es) 2020-01-16 2024-11-18 Janssen Pharmaceuticals Inc Mutante de FimH, composiciones con el mismo y uso del mismo
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CN117105888A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 一种mpla酰基链中间体的合成方法
CN117105783A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 R-3-酰氧基-烷酸的合成方法、中间体及应用
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
JPS6153295A (ja) 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US6544728B1 (en) 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US6054565A (en) * 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (ja) 1986-07-01 1995-06-14 第一製薬株式会社 ジサツカライド誘導体含有鎮痛剤
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE122007000023I1 (de) 1991-07-19 2007-08-09 Univ Queensland St Lucia Impfsstoff gegen Humanes Papillomavirus (typ 18)
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
BR9206310A (pt) 1991-07-25 1995-04-25 Idec Pharma Corp Indução de respostas citotóxicas de linfócitos T.
DE69207603T2 (de) 1991-08-16 1996-09-12 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
ES2129461T3 (es) 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0647140B1 (en) 1992-06-25 2007-12-12 Georgetown University Papillomavirus vaccines
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
ES2242955T4 (es) 1993-03-09 2010-04-12 The University Of Rochester Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral.
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE69434745T2 (de) * 1993-11-02 2006-10-05 Matsushita Electric Industrial Co., Ltd., Kadoma Verfahren zur Herstellung eines Aggregats von Mikro-Nadeln aus Halbleitermaterial und Verfahren zur Herstellung eines Halbleiterbauelements mit einem solchen Aggregat
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (sv) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
DE59511047D1 (de) 1994-10-07 2006-06-14 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
WO1996024379A1 (en) 1995-02-08 1996-08-15 Takara Shuzo Co., Ltd. Cancer control
JP3958360B2 (ja) 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997011708A1 (en) 1995-09-29 1997-04-03 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US6235724B1 (en) * 1996-07-03 2001-05-22 Eisai Co., Ltd. Injections containing lipid a analogues and process for the preparation thereof
CA2265889A1 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JPH10131046A (ja) 1996-10-29 1998-05-19 Nikka Chem Co Ltd 繊維の耐久性ｐＨ緩衝加工方法
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
DE69831222T2 (de) 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CN1227360C (zh) 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
AU764036B2 (en) 1998-02-12 2003-08-07 Wyeth Holdings Corporation Vaccines comprising interleukin-12 and herpes simplex viral antigen
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
KR20010041629A (ko) 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
GB2336310B (en) * 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6630161B1 (en) 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
AU766994B2 (en) 1998-08-25 2003-10-30 Ronald J. Gallenberg Beach cleaning apparatus and method
JP3943334B2 (ja) 1998-09-01 2007-07-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体含有注射剤の評価方法
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2000095694A (ja) * 1998-09-24 2000-04-04 Sankyo Co Ltd 新規な医療用薬剤
AU5980899A (en) 1998-09-25 2000-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US7001770B1 (en) * 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
CN101926993B (zh) * 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
CA2369883A1 (en) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. Method for judging autoimmune disease, method for detecting anti-reg protein autoantibody and diagnostics for autoimmune diseases
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
US6685699B1 (en) * 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
AU6884200A (en) 1999-08-26 2001-03-19 Biovitrum Ab Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6218186B1 (en) * 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
EP1232168B1 (en) 1999-11-15 2011-08-03 Oncothyreon Inc. Synthetic lipid-a analogs and uses thereof
US20020064801A1 (en) * 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) * 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001055362A2 (en) 2000-01-31 2001-08-02 The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
KR100829674B1 (ko) 2000-05-19 2008-05-16 코릭사 코포레이션 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법
AU2001265219A1 (en) * 2000-05-31 2001-12-11 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
AU2002223970A1 (en) 2000-10-06 2002-04-15 H. Henrich Paradies Kyberdrug as autovaccines with immune-regulating effects
IL155282A0 (en) 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
CA2462951A1 (en) 2001-01-26 2003-01-16 Jeffrey A. Lyon Isolation and purification of plasmodium falciparum merozoite protein-142
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
AU2002306896B2 (en) * 2001-03-26 2007-04-26 Walter Reed Army Institute Of Research Plasmodium falciparum AMA-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) * 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US7078180B2 (en) 2001-09-05 2006-07-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
MXPA04007491A (es) * 2002-02-04 2004-11-10 Corixa Corp Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
RU2288723C2 (ru) * 2002-02-04 2006-12-10 Корикса Корпорейшн Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
EP1549322B1 (en) 2002-05-09 2010-02-17 Oncothyreon Inc. Lipid a and other carbohydrate ligand analogs
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2862062B1 (fr) 2003-11-06 2005-12-23 Oreal Lipide a et composition topique, notamment cosmetique, le comprenant
ES2657392T3 (es) * 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8563523B2 (en) * 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
PT2437753T (pt) * 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Ｒｆパワーモジュール
EP3711768A1 (en) * 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016028042A (ja) * 2009-06-05 2016-02-25 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント

Also Published As

Publication number Publication date
ES2606563T3 (es) 2017-03-24
SI2437753T1 (sl) 2016-12-30
PL2437753T3 (pl) 2017-03-31
US20100310602A1 (en) 2010-12-09
TWI549688B (zh) 2016-09-21
CN105131051B (zh) 2020-07-10
US9480740B2 (en) 2016-11-01
CN102481312B (zh) 2015-07-15
WO2010141861A1 (en) 2010-12-09
CY1118347T1 (el) 2017-06-28
EP2437753B1 (en) 2016-08-31
JP6251431B2 (ja) 2017-12-20
JP2017137327A (ja) 2017-08-10
HUE031051T2 (en) 2017-06-28
IL216669A0 (en) 2012-02-29
CN102481312A (zh) 2012-05-30
CA2764374A1 (en) 2010-12-09
BRPI1011072B1 (pt) 2021-09-28
LT2437753T (lt) 2016-12-12
HRP20161585T1 (hr) 2016-12-30
BRPI1011072A2 (pt) 2016-04-12
RU2560182C2 (ru) 2015-08-20
MX2011012836A (es) 2012-04-20
IL216669A (en) 2016-04-21
TW201102085A (en) 2011-01-16
MX393384B (es) 2025-03-24
US10632191B2 (en) 2020-04-28
RU2732574C2 (ru) 2020-09-21
US20180028649A1 (en) 2018-02-01
AU2010256461A1 (en) 2012-01-12
TW201544120A (zh) 2015-12-01
US9814772B2 (en) 2017-11-14
CA2764374C (en) 2019-11-19
PT2437753T (pt) 2016-11-23
DK2437753T3 (en) 2016-12-19
JP2012528892A (ja) 2012-11-15
TWI494125B (zh) 2015-08-01
EP2437753A4 (en) 2012-12-05
RU2015129468A (ru) 2015-12-27
SMT201600437B (it) 2017-01-10
EP3124491B1 (en) 2019-10-30
US20140322268A1 (en) 2014-10-30
EP2437753A1 (en) 2012-04-11
EP3124491A1 (en) 2017-02-01
JP2016028042A (ja) 2016-02-25
RU2015129468A3 (OSRAM) 2019-01-21
RU2020129844A (ru) 2022-03-10
AU2010256461B2 (en) 2016-03-17
MX360448B (es) 2018-11-01
IL242992B (en) 2018-01-31
CN105131051A (zh) 2015-12-09
US8722064B2 (en) 2014-05-13
US20170182155A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
JP6251431B2 (ja) 合成グルコピラノシル脂質アジュバント
EP3403667B1 (en) Vaccine composition containing synthetic adjuvant
HK1234065A1 (en) Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
HK1234065B (en) Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
HK1169041B (en) Synthetic glucopyranosyl lipid adjuvants and vaccine composition containing them
HK1262792B (en) Vaccine composition containing synthetic adjuvant
HK1262792A1 (en) Vaccine composition containing synthetic adjuvant
HK1174283B (en) Vaccine composition containing synthetic adjuvant
HK1174830B (en) Vaccine composition containing synthetic adjuvant
HK1172267B (en) Vaccine composition containing synthetic adjuvant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150819

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151023

R150 Certificate of patent or registration of utility model

Ref document number: 5830015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250